加载中
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
前收盘价
US$6.865
−US$0.175 · -2.49%
盘后
US$6.86
−US$0.005 · -0.07%
10月12日 19:24 ET
盘中时间采用ET。市场数据可能有所延迟。
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
日内区间
当前US$6.865
52周区间
当前US$6.865
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
49
合理估值
情绪
42
多空交织
风险
86
极高风险
动量
35
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
日内区间
当前US$6.865
52周区间
当前US$6.865
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.17亿 USD | 1.06亿 USD | 1.13亿 USD | 1.02亿 USD | 733.8万 USD |
| 销货成本 | 541.6万 USD | 388.4万 USD | 463.6万 USD | 479.3万 USD | 767万 USD |
| 毛利 | 1.11亿 USD | 1.02亿 USD | 1.09亿 USD | 9749.7万 USD | −33.2万 USD |
| 研究与开发 | 1369.8万 USD | 1202.4万 USD | 1378万 USD | 1668.6万 USD | 6457.4万 USD |
| 销售、一般及管理费用 | 8598.3万 USD | 7362万 USD | 7582.1万 USD | 7160.8万 USD | 1882万 USD |
| 营业费用 | 9968.1万 USD | 8571万 USD | 1.76亿 USD | 8829.4万 USD | 8339.4万 USD |
| 利息收入 | 174.7万 USD | 154.7万 USD | 104.4万 USD | 72.6万 USD | 3.9万 USD |
| 折旧和摊销 | 248.1万 USD | 158.8万 USD | 111.4万 USD | 112.9万 USD | 29万 USD |
| 营业利润 | 1149.1万 USD | 1622.9万 USD | −6723万 USD | 920.3万 USD | −8372.6万 USD |
| 净利润 | 502.7万 USD | 1208.5万 USD | −9293.3万 USD | 230.2万 USD | −8793.3万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$17.00
上涨空间 147.63%| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2023年1月13日 | US$0.24Quarterly | 2023年1月5日 | — |
股息 | 2022年9月21日 | US$1.43Quarterly | 2022年9月6日 | — |
股息 | 2015年8月20日 | US$0.569Quarterly | — | — |
除息 2023年1月13日
US$0.24
Quarterly
2023年1月5日登记
除息 2022年9月21日
US$1.43
Quarterly
2022年9月6日登记
除息 2015年8月20日
US$0.569
Quarterly
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI403.83万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM281.36万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF156.82万0.00%954亿 USD0.05%US$233.52-0.63%
Schwab U.S. Small-Cap ETFSCHA126.8万0.01%218.24亿 USD0.03%US$32.66-0.40%
iShares Russell 2000 Growth ETFIWO69.93万0.01%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO69.48万0.00%180亿 USD0.06%US$112.27-0.35%
WisdomTree U.S. SmallCap FundEES13.55万0.02%6.81亿 USD0.38%US$65.46-0.05%
Schwab U.S. Broad Market ETFSCHB12.35万0.00%453.77亿 USD0.03%US$29.88-0.10%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOWisdomTree U.S. SmallCap FundEESSchwab U.S. Broad Market ETFSCHBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
